Medovate unveils US launch plans for regional anaesthesia innovation


04-02-2020
SAFIRA driver and syringe with foot pedal operator mechanism

Medovate is breaking into the US market with the launch of the FDA approved SAFIRA regional anaesthesia innovation at ASRA 2020 (the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting), and membership of the Association of British Healthcare Industries (ABHI) US Accelerator programme. 

Medovate is breaking into the US market with the launch of the FDA approved SAFIRA regional anaesthesia innovation, at ASRA 2020 (the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine), taking place in San Francisco on the 23rd - 25th April.

At ASRA 2020, US clinicians will have their first opportunity to see Medovate’s SAFIRA in action. As silver sponsors of the conference, Medovate will be running demonstrations and allowing experts in regional anaesthesia and pain medicine to view the device up close, as well as to meet Medovate’s US-based distributors.

The launch of SAFIRA comes just two years since Medovate itself was established, and is evidence of the company’s ability to fast-track the development and commercialisation of medtech solutions arising from within the National Health Service (NHS), for the benefit of healthcare systems around the world. Medovate now enjoys an expanding portfolio of innovations from the NHS and beyond, with a particular focus on the fields of anaesthesia, airway management, critical care and surgery.

SAFIRA (SAFer Injection for Regional Anaesthesia) is set to radically advance standard clinical practice with regards to regional blocks in a number of ways. Firstly, the device contains a safety feature that helps prevent anaesthetic being injected at unsafe pressures, reducing the risk of significant or peripheral nerve damage.

In addition, because SAFIRA makes the regional anaesthesia process a one-person procedure by a single anaesthetist (current processes require two operators, an anaesthetist and a technician), he or she has full control throughout. This has the knock-on effect of reducing theatre time, and is expected to deliver savings of up to $102 per regional block. An estimated 10 million regional blocks are carried out each year in the US.

To extend its reach into the US market, Medovate has also joined the Association of British Healthcare Industries (ABHI) US Accelerator. This 12-month programme is designed to support medical device companies seeking to access US buyers and will allow Medovate to plug into ABHI’s expertise and connections within the US, including major hospitals and Group Purchasing Organizations (GPOs).

Crucially, SAFIRA has been designed so that its application for regional anaesthesia procedures is the same in all markets, meaning that no additional modifications are required for the US or any other market, and that the product can be seamlessly integrated into the clinical pathway.

Stuart Thomson, Managing Director, Medovate, commented:
“Launching in the US is a statement both of our ambitions for international expansion and of the confidence we have in the medtech devices within our portfolio. With a healthy innovation pipeline, including a ground-breaking device for airway management to come soon, we hope that the launch of SAFIRA is the first in a series of exciting new developments for Medovate this year.”

 

Medovate is a medical device company dedicated to the development and commercialisation of innovative medical technologies created within the NHS and beyond to improve patient care.

Medovate Ltd